Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 15/20 | 0.71 |
| ▸ | ACE2 | Q9BYF1 | 6/20 | 0.57 |
| ▸ | LTA4H | P09960 | 2/20 | 0.53 |
| ▸ | DPP4 | P27487 | 2/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.51 |
| ▸ | FAP | Q12884 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351429 | 0.91 | ACE (0.59) | ACEACE2DPP4 | |
| SCHEMBL31657795 | 0.87 | ACE (0.55) | ACEACE2DPP4 | |
| SCHEMBL30001593 | 0.87 | SLC6A2 (0.57) | ACEACE2 | |
| SCHEMBL30066883 | 0.85 | ACE (0.55) | ACEACE2 | |
| SCHEMBL29414524 | 0.84 | ACE (0.59) | ACEACE2LTA4HDPP4DPP8 | |
| SCHEMBL31411888 | 0.83 | ACE (0.55) | ACEACE2 | |
| SCHEMBL29589786 | 0.83 | ACE (0.56) | ACEACE2 | |
| Hydrochloric Acid SCHEMBL11124018 | 0.83 | ACE (1.00) | ACEACE2 | |
| Hydrochloric Acid SCHEMBL11281190 | 0.83 | ACE (1.00) | ACEACE2 | |
| SCHEMBL9053553 | 0.83 | SLC6A2 (0.63) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4237008-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | Elucida Oncology, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-4103236-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | Elucida Oncology, Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| WO-2022093793-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022093800-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | ACE 1190/4885ACE2 1622/4885LTA4H 3533/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | ACE 486/4885ACE2 675/4885LTA4H 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.